Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Zosano Pharma	CohBar	Merrimack Pharmaceuticals	Vascular Biogenics	Aeterna Zentaris
Symbol	NASDAQ:ZSAN	NASDAQ:CWBR	NASDAQ:MACK	NASDAQ:VBLT	NASDAQ:AEZS
Price Information
Current Price	$0.81	$1.12	$7.32	$1.74	$0.85
52 Week Range	Buy	Buy	N/A	Buy	N/A
MarketRank™
Overall Score	1.4	1.5	1.1	1.3	0.6
Analysis Score	3.5	3.5	0.0	3.5	0.0
Community Score	2.9	3.3	2.9	2.4	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	2.5	0.0	0.0
Earnings & Valuation Score	0.6	0.0	0.0	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	N/A	Buy	N/A
Consensus Price Target	$2.17	$5.50	N/A	$4.13	N/A
% Upside from Price Target	168.05% upside	391.07% upside	N/A	137.07% upside	N/A
Trade Information
Market Cap	$99.49 million	$70.44 million	$101.78 million	$85.77 million	$57.04 million
Beta	2.98	2.96	2.55	1.17	2.1
Average Volume	10,132,435	683,158	91,195	1,000,797	18,200,803
Sales & Book Value
Annual Revenue	N/A	N/A	N/A	$560,000.00	$530,000.00
Price / Sales	N/A	N/A	N/A	149.72	100.55
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.40 per share	$0.19 per share	$1.30 per share	$1.00 per share	($0.12) per share
Price / Book	N/A	N/A	N/A	1.74	-7.09
Profitability
Net Income	$-37,590,000.00	$-13,050,000.00	$-17,330,000.00	$-19,460,000.00	$-6,040,000.00
EPS	($2.29)	($0.30)	N/A	($0.54)	N/A
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	-2,692.41%	-369.10%
Return on Equity (ROE)	-227.55%	-124.02%	-14.94%	-61.77%	-125.54%
Return on Assets (ROA)	-79.80%	-80.21%	-12.96%	-47.23%	-21.45%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.16%	N/A	N/A	N/A
Current Ratio	0.68%	10.26%	8.42%	5.16%	12.98%
Quick Ratio	0.68%	10.26%	8.42%	5.16%	12.77%
Ownership Information
Institutional Ownership Percentage	10.07%	10.20%	52.25%	4.50%	2.44%
Insider Ownership Percentage	6.10%	39.36%	21.60%	N/A	N/A
Miscellaneous
Employees	56	11	27	38	12
Shares Outstanding	106.29 million	61.79 million	13.41 million	48.19 million	62.68 million
Next Earnings Date	5/13/2021 (Estimated)	5/13/2021 (Estimated)	5/6/2021 (Estimated)	5/13/2021 (Estimated)	5/5/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Aeterna Zentaris Inc. (NASDAQ:AEZS) Stock Could Reward Investors With a 411.36% Gain marketingsentinel.com - April 19 at 1:12 PM
	Analysts think Aeterna Zentaris Inc. (NASDAQ:AEZS) could rise 411.36% from current levels stocksregister.com - April 19 at 1:12 PM
	Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update americanbankingnews.com - April 15 at 1:48 AM
	Aeterna Zentaris Inc. [AEZS] Stock trading around $0.94 per share: What’s Next? dbtnews.com - April 13 at 6:38 PM
	AEterna Zentaris Stock Shows Every Sign Of Being Significantly Overvalued finance.yahoo.com - April 13 at 7:33 AM
	What Do Wall Street Analysts Think About Aeterna Zentaris Inc. (NASDAQ:AEZS) Stock? stocksregister.com - April 13 at 1:00 AM
	Why should you add Aeterna Zentaris Inc. (AEZS) to your portfolio? marketingsentinel.com - April 12 at 9:59 AM
	Critical Analysis: Trillium Therapeutics (NASDAQ:TRIL) & Aeterna Zentaris (NASDAQ:AEZS) americanbankingnews.com - April 8 at 12:20 PM
	Aeterna Zentaris (NASDAQ:AEZS) Share Price Crosses Above 200 Day Moving Average of $0.69 americanbankingnews.com - April 3 at 12:36 AM
	Should Aeterna Zentaris (TSE:AEZS) Be Disappointed With Their 100% Profit? finance.yahoo.com - March 30 at 8:07 AM
	If You’re Not Bullish on Aeterna Zentaris Inc. (NASDAQ:AEZS) Now, You’ll Kick Yourself Later stocksregister.com - March 29 at 10:25 AM
	Analysts Say Aeterna Zentaris Inc. (NASDAQ:AEZS) Can Really Get to $4.5 in 12 Months marketingsentinel.com - March 26 at 12:05 PM
	Aeterna Zentaris Inc. [AEZS] Stock trading around $1.18 per share: What’s Next? dbtnews.com - March 26 at 7:05 AM
	Analysts Say You Should Buy Your Position in Aeterna Zentaris Inc. (NASDAQ:AEZS) stocksregister.com - March 26 at 12:53 AM
	Aeterna Zentaris: Q4 Earnings Snapshot finance.yahoo.com - March 25 at 9:50 AM
	Aeterna Zentaris: Q4 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - March 25 at 9:50 AM
	Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 25 at 9:50 AM
	Analyzing The Price Action In AEterna Zentaris Stock Today msn.com - March 15 at 2:51 PM
	Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate finance.yahoo.com - March 15 at 2:51 PM
	AEZS Stock Price Increases Over 10% Pre-Market: Why It Happened pulse2.com - March 15 at 9:51 AM
	Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ... apnews.com - March 15 at 9:51 AM
	Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19 finance.yahoo.com - March 15 at 9:51 AM
	Stocks in play: Aeterna Zentaris Inc ca.finance.yahoo.com - March 11 at 12:42 PM
	Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism finance.yahoo.com - March 11 at 12:42 PM
	Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - February 24 at 12:38 PM

Date	Company	Brokerage	Action
3/22/2021	Zosano Pharma	Maxim Group	Boost Price Target
11/25/2020	Zosano Pharma	HC Wainwright	Lower Price Target
10/22/2020	Zosano Pharma	BTIG Research	Lower Price Target
11/15/2019	Zosano Pharma	Cantor Fitzgerald	Lower Price Target
3/31/2021	CohBar	Aegis	Reiterated Rating
3/31/2021	CohBar	Chardan Capital	Boost Price Target
11/10/2020	CohBar	Roth Capital	Reiterated Rating
10/15/2020	CohBar	WBB Securities	Initiated Coverage
5/28/2020	CohBar	Brookline Capital Management	Initiated Coverage
11/7/2018	Merrimack Pharmaceuticals	Cowen	Reiterated Rating
10/20/2018	Merrimack Pharmaceuticals	Robert W. Baird	Set Price Target
6/25/2018	Merrimack Pharmaceuticals	JPMorgan Chase & Co.	Downgrade
5/14/2020	Vascular Biogenics	Oppenheimer	Reiterated Rating
6/27/2019	Vascular Biogenics	CIBC	Initiated Coverage

(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources